Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZOTECT: Zoledronic acid in prostate or breast cancer with bone metastasis
NCT00334139Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2006
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zoledronic acid in bone metastasis, sponsored by Novartis. Primary endpoint: Bone turnover assessed by bone turnover parameters. Started May 2006; status: completed.
02
Drugs
zoledronic acid
03
Conditions
bone metastasis
Beyond the preview
Go deeper on NCT00334139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00334139.